Middleway Nutrition
Evidence-based GLP-1 and peptide science.
Clear clinical research, dosing context, safety tradeoffs, and practical guides organized into two focused archives.
Latest Articles
20 articles
Can GLP-1 Cause Depression? What the FDA, EMA, and Large Cohorts Actually Found
An EMA signal in July 2023 raised the alarm. The big follow-up studies, including a 240,000-patient EHR analysis showing semaglutide cut suicidal ideation risk by 73%, told a different story. Here is the honest read.
GLP-1Can GLP-1 Cause Pancreatitis? An Honest Look at the 2026 Evidence
Trial data shows pancreatitis is rare on GLP-1s — roughly 0.3–0.4% of patients, similar to placebo in most studies. But the signal is real in some analyses, especially with gallstones and rapid weight loss. Here is the per-drug picture, the meta-analysis findings, and what to watch for.
GLP-1GLP-1 and Thyroid Cancer: The Boxed Warning, the Rat Study, and What the Human Data Actually Show (2026)
Every GLP-1 carries an FDA boxed warning for medullary thyroid carcinoma. The warning came from rat studies. Large human cohort studies — 92,000+ GLP-1 users vs 2.4 million controls — have not confirmed the signal. Here is the full picture.
GLP-1GLP-1 and the Gallbladder: Stone Risk, Symptoms, and What Changes If You've Had Yours Removed
Semaglutide raises gallbladder disorders to 2.6% vs 1.2% on placebo, and the JAMA meta-analysis of 76 trials puts the weight-loss-dose relative risk at 2.29. Two mechanisms collide: GLP-1 suppresses the cholecystokinin signal that empties the gallbladder, and rapid weight loss supersaturates bile with cholesterol. Here is what changes if you still have your gallbladder, and what changes if you don't.
GLP-1GLP-1 and Gastroparesis: What the Evidence Actually Shows in 2026
Gastroparesis is the most-litigated GLP-1 complication. The 2025 cohort data shows a 3.3–6.1× relative risk in obesity patients and a 3.67× relative risk in T2D — but absolute incidence is under 1%, and most cases resolve after stopping. Here is the full clinical picture.
GLP-1Rybelsus Guide: Oral Semaglutide for Type 2 Diabetes (2026)
Rybelsus is the only FDA-approved GLP-1 pill for type 2 diabetes — 3, 7, and 14 mg daily doses, strict empty-stomach rule, A1C drops of 1.0-1.5%, and a $1,027.51 monthly list price. Here is what the PIONEER trials, SNAC absorption, and real-world use actually show.
GLP-1Trulicity Guide: Weekly Dulaglutide for Type 2 Diabetes (2026)
Trulicity (dulaglutide) is Eli Lilly's once-weekly GLP-1 injection, approved in 2014 for type 2 diabetes. Doses run 0.75 to 4.5 mg, the REWIND trial showed a 12% MACE reduction, and the list price sits near $887 per month. Here is the full breakdown.
GLP-1Victoza Guide: Daily Liraglutide for Type 2 Diabetes (2026)
Victoza (liraglutide) is the original daily GLP-1 injection for type 2 diabetes — approved in 2010, doses of 0.6/1.2/1.8 mg, A1C drops of 1.0-1.5%, and the LEADER trial cardiovascular benefit. With generic liraglutide now available in 2026, this drug has a fresh second life.
GLP-1GLP-1 Insurance Coverage 2026: Medicare Bridge, Medicaid by State, Savings Cards, FSA/HSA
How to actually get Wegovy or Zepbound covered in 2026. Commercial copay cards to $25, the new Medicare GLP-1 Bridge at $50/month starting July 2026, Medicaid coverage in 13 states, FSA/HSA rules, prior auth, and how to appeal a denial.
GLP-1GLP-1 at Costco, CVS, Walmart, and Walgreens: A 2026 Pharmacy Pricing Map
Where to physically fill a Wegovy, Ozempic, or Zepbound prescription in 2026 — cash prices, member programs, retail clinic visits, and manufacturer-direct pickup compared across the major chains.
GLP-1GLP-1 and Pregnancy: Washout Timing, Breastfeeding, and Unintended Exposure (2026)
Semaglutide and tirzepatide are contraindicated in pregnancy. Here is the exact washout period before conception, what to do if pregnancy happens unexpectedly, what current data show about birth defects, and how breastfeeding guidance differs between injection and oral forms.
GLP-1Hims GLP-1 Review: The $49 Pill Era Ended in March 2026 — What's Left
Hims settled with Novo Nordisk on March 9, 2026 and exited compounded semaglutide for new patients. Pricing is now $249-$399/month for branded drugs plus a $149 membership. Worth it?
GLP-1GLP-1 Before and After: Month-by-Month Weight Loss Timeline (Real Data)
Trials show 15–22% mean weight loss over 18 months on a GLP-1. Real-world data is much lower — about 2% at 72 weeks on older drugs at standard doses. Here is the full curve and what drives the gap.
GLP-1GLP-1 Reviews 2026: What Real Patients Rate Zepbound, Wegovy, Ozempic, and Mounjaro
Aggregated patient reviews across Drugs.com and WebMD: Zepbound 8.7/10, Mounjaro 8.4/10, Wegovy 7.4/10, Ozempic 6.7/10. What people love, what they hate, and why fewer than 1 in 4 stay on past a year.
GLP-1GLP-1 Supplements: Drops, Gummies, and Boosters — What's In Them, What They Cost, What They Do
Injectable semaglutide raises GLP-1 by over 1,000%. The best OTC supplement gummies raise it by ~17%. Here's the brand-by-brand breakdown — ingredients, prices, evidence, and what they're really worth.
GLP-1GLP-1 and GIP: How Two Gut Hormones Drive the Most Effective Weight-Loss Drugs
GLP-1 gets the headlines, but it is the addition of GIP that makes tirzepatide outperform semaglutide. The mechanism is surprising — and tirzepatide actually binds GLP-1 weaker than the hormone it mimics.
GLP-1GLP-1 Benefits for Women: PCOS, Menopause, Fertility, and What's Different in 2026
Women lose more total weight than men on GLP-1s on average but progress slightly slower per dose. The drugs normalize cycles in ~80% of PCOS responders, drive an Ozempic baby boom in once-infertile women, and reduce breast cancer risk signals — while raising bone density and hair loss concerns unique to female biology.
GLP-1GLP-1 and Kidney Disease: FLOW Trial Data and Ozempic's FDA-Approved CKD Indication
FDA approved Ozempic (semaglutide) on January 28, 2025 to slow kidney disease progression in adults with type 2 diabetes and CKD. The FLOW trial in 3,533 patients showed a 24% reduction in major kidney events — independent of weight loss.
GLP-1How to Boost GLP-1 Naturally: Foods, Exercise, and Habits That Actually Work
Your body makes GLP-1 every time you eat — but DPP-4 destroys it within 1-2 minutes. Protein, soluble fiber, healthy fats, fermented foods, and exercise amplify the pulse. Here's the evidence-based playbook.
GLP-1GLP-1 for Heart Failure: STEP-HFpEF, SUMMIT, and Why HFpEF Is Where the Data Lives
Semaglutide and tirzepatide both improve symptoms in obesity-related HFpEF. STEP-HFpEF: +7.8 KCCQ points, -13.3% weight. SUMMIT: 38% lower risk of CV death or worsening heart failure with tirzepatide.